Immunovant ( (IMVT) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immunovant’s stock has been under pressure due to a challenging regulatory environment and concerns about its recent performance. Goldman Sachs resumed coverage with a Neutral rating and a price target of $18, while H.C. Wainwright lowered its price target from $51 to $35. These moves reflect a cautious stance among analysts, highlighting the regulatory and market challenges impacting the company’s growth prospects.
More about Immunovant
YTD Price Performance: -31.36%
Average Trading Volume: 1,299,447
Technical Sentiment Signal: Sell
Current Market Cap: $2.89B
For further insights into IMVT stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.